Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results
Cytek Biosciences (NASDAQ:CTKB) reported quarterly earnings, posting an EPS of ($0.04), missing the consensus estimate of $0.01. Revenue was $52.29 million, exceeding expectations of $51.49 million. The company has a negative return on equity of 1.66% and a net margin of 3.27%. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a price target of $5.60. Institutional investors own 69.46% of the company, and recent trading saw shares rise to $4.01.
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05), FiscalAI reports. The company had revenue of $52.29 million for the quarter, compared to analyst estimates of $51.49 million. Cytek Biosciences had a negative net margin of 3.27% and a negative return on equity of 1.66%. Cytek Biosciences updated its FY 2025 guidance to EPS.
Get Cytek Biosciences alerts:
Cytek Biosciences Stock Performance
Shares of NASDAQ:CTKB traded up $0.10 during midday trading on Wednesday, reaching $4.01. The company had a trading volume of 956,227 shares, compared to its average volume of 970,038. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $7.63. The company has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $3.60. The firm has a market cap of $510.17 million, a price-to-earnings ratio of -80.20 and a beta of 1.33.
Hedge Funds Weigh In On Cytek Biosciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its stake in Cytek Biosciences by 150.9% in the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after purchasing an additional 4,343 shares during the period. Captrust Financial Advisors acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $43,000. Tower Research Capital LLC TRC boosted its position in Cytek Biosciences by 338.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,760 shares of the company's stock worth $67,000 after acquiring an additional 15,250 shares during the period. Quantbot Technologies LP acquired a new stake in Cytek Biosciences during the 2nd quarter worth about $84,000. Finally, Strs Ohio acquired a new stake in shares of Cytek Biosciences during the first quarter worth approximately $105,000. Institutional investors and hedge funds own 69.46% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Cytek Biosciences in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Cytek Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $5.60.
Check Out Our Latest Research Report on CTKB
About Cytek Biosciences
(Get Free Report)Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
- Five stocks we like better than Cytek Biosciences
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Cash-Rich Stocks With High Growth Potential Right Now
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Vertical Aerospace Stock Could Double After This Flight Test
- How to Use Stock Screeners to Find Stocks
- Amazon: Breakout Confirmed—Here’s Where It Could Go Next
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Cytek Biosciences Right Now?
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
